Clinical Research organisations during the recession – Frost report on CRO’s
Some people may speculate what is to become of the clinical research organisation (CRO) industry while the nation slowly improves from the recent recession, but according to a recent reportperformed by Frost & Sullivan, the CRO industry will keep on groing. Throughout this current environment, biotech and pharma companies are less likely to rely on or spend on internal ways to perform their clinical trials. However, somebody has to do them…
A note of warning has also been reported, where “American CRO Market-Key Therapeutic Areas” expects that battling biotech and pharma organisations are likely to fail to pay current ongoing projects. However, this trend is not expected to last over the long term.
Barath Shankar Subramanian, senior industry analyst for Frost and Sullivan, pointed out that the CRO annual revenue growth is down from the fourteen to fifteen percent region last year to ten percent this year.
Expansion Forecasts – for pharmacology companies or CRO’s
Although, this is not all bad news – Subramanian claims that the industry’s annual revenues will double from now until the year 2015, growing from a current 12.91 billion to $22.87 billion in the years to come. This, he says, will be due to sponser firms increasingly adopting tactical partnerships with smaller services firms or CROs. “After 10 years of talking about such relationships, CROs and pharma companies are beginning to forge them,” he says.
Subramanian uses the immense Eli Lilly/Covance partnership as an example, which came in to effect in August last year, where Covance has outsourced $1.6 billion worth of drug development business to Lilly over the next 10 years.
Subramanian says: “That’s the flavor of the season, we’re seeing some new models being explored when previously it was purely transactional, with CROs taking a wait and watch attitude toward strategic partnerships.”
A further development is CROs or clinical research organisations allowing sponsors to keep hold of hopeful molecules for longer into the research cycle. Biotechnology and Pharmaceutical companies just starting out would often out-licence products after Phases I and II; resulting in a vast amount of uncertainty of the future of the assignment. These days, on the other hand, more of these firms can retain products in their pipeline for longer, which means bringing them closer to the market. This is made possible by the cost savings associated with CRO partnerships. This is a great step forward for sponsors and CROs.
Tip from the Author: clinical studies conducted in the UK by a professional institute of clinical research is the best choice for aquiring the most accurate data.
* Make sure that you consult your doctor before taking any medical advice of any kind.